CIPLA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,447 INR | -1.32% |
|
-2.64% | +16.12% |
| May. 31 | Cipla's Global Chief Technology Officer Retires | MT |
| May. 30 | India's pharma export sales to grow faster this year, trade body says | RE |
| Sales 2024 | 258B 3.09B | Sales 2025 * | 280B 3.36B | Capitalization | 1,169B 14.01B |
|---|---|---|---|---|---|
| Net income 2024 | 41.22B 494M | Net income 2025 * | 46.64B 559M | EV / Sales 2024 | 4.69 x |
| Net cash position 2024 * | 55.83B 669M | Net cash position 2025 * | 57.4B 688M | EV / Sales 2025 * | 3.97 x |
| P/E ratio 2024 |
29.3
x | P/E ratio 2025 * |
25.1
x | Employees | 32,323 |
| Yield 2024 * |
0.58% | Yield 2025 * |
0.68% | Free-Float | 67.03% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cipla Limited
More recommendations
More press releases
More news
| 1 day | -1.32% | ||
| 1 week | -2.64% | ||
| 1 month | +3.37% | ||
| 3 months | -2.24% | ||
| 6 months | +19.38% | ||
| Current year | +16.12% |
1 week
1 440.00
1 497.60
1 month
1 317.251 504.55
Current year
1 252.101 519.00
1 year
954.651 519.00
3 years
850.001 519.00
5 years
355.301 519.00
10 years
355.301 519.00
| Managers | Title | Age | Since |
|---|---|---|---|
Umang Vohra
CEO | Chief Executive Officer | 52 | 15-09-30 |
Ashish Adukia
DFI | Director of Finance/CFO | - | 22-08-15 |
| Chief Tech/Sci/R&D Officer | - | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ashok K. Sinha
BRD | Director/Board Member | 72 | 13-07-15 |
| Chairman | 87 | 72-07-20 | |
| Director/Board Member | 83 | 77-08-15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.99% | 6 M€ | +6.07% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 1,447 | -1.32% | 3,270,743 |
| 24-05-30 | 1,467 | -1.80% | 1,732,140 |
| 24-05-29 | 1,494 | +0.95% | 1,607,691 |
| 24-05-28 | 1,479 | +0.05% | 784,496 |
| 24-05-27 | 1,479 | -0.52% | 1,393,334 |
Delayed Quote NSE India S.E., May 31, 2024 at 07:43 am EDT
More quotes
Cipla specializes in development, manufacturing and marketing of pharmaceutical products. The group provides prescription products and OTC medicines for the treatment of cardiovascular, ophthalmic and dermatological diseases, respiratory troubles, cancers, allergies, infections etc. Besides, Cipla develops and sells veterinary products.
Net sales by source of income break down between sale of products (96.9%) and services (3.1%).
Net sales are distributed geographically as follows: India (39.4%), the United States (18.5%), South Africa (17%) and other (25.1%).
Sector
Pharmaceuticals
Calendar
2024-06-02
- BofA India Conference
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
1,447
INR
Average target price
1,482
INR
Spread / Average Target
+2.42%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.12% | 14B | |
| +15.91% | 41.97B | |
| +22.40% | 22.34B | |
| +18.48% | 15.25B | |
| +45.12% | 12.06B | |
| -0.05% | 6.79B | |
| -9.58% | 6.8B | |
| -8.87% | 5.73B | |
| +14.18% | 5.49B | |
| +4.17% | 4.62B |
- Stock Market
- Equities
- CIPLA Stock
